FSNUY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 15:46):

Stats
Today's Volume	32 864.00
Average Volume	50 122.00
Market Cap	17.92B
EPS	$0 ( 2024-03-19 )
Next earnings date	( $0 ) 2024-06-04
Last Dividend	$0.247 ( 2023-05-18 )
Next Dividend	$0 ( N/A )
P/E	39.77
ATR14	$0.0150 (0.19%)

Fresenius SE & Co. KGaA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fresenius SE & Co. KGaA Financials

Annual	2023
Revenue:	$22.30B
Gross Profit:	$5.06B (22.68 %)
EPS:	$-1.050

FY	2023
Revenue:	$22.30B
Gross Profit:	$5.06B (22.68 %)
EPS:	$-1.050

FY	2022
Revenue:	$40.84B
Gross Profit:	$10.73B (26.26 %)
EPS:	$3.77

FY	2021
Revenue:	$37.52B
Gross Profit:	$10.31B (27.48 %)
EPS:	$0.815

Financial Reports:

No articles found.

Fresenius SE & Co. KGaA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.247 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Fresenius SE & Co. KGaA Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 6.26 - average (75.56%) | Divividend Growth Potential Score: 0.545 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.119	2013-05-15
Last Dividend	$0.247	2023-05-18
Next Dividend	$0	N/A
Payout Date	2023-05-30
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$2.15	--
Avg. Dividend % Per Year	0.00%	--
Score	1.63	--
Div. Sustainability Score	6.26
Div.Growth Potential Score	0.545
Div. Directional Score	3.40	--

Next Divdend (Est)
(2025-04-04)

$0.254 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.63

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
MHGVY	Ex Dividend Knight	2023-09-01	Quarterly	0.00%
BLSFY	Ex Dividend Knight	2023-09-11	Semi-Annually	0.00%
TSRYY	Ex Dividend Knight	2023-08-30	Semi-Annually	0.00%
GLPEY	Ex Dividend Knight	2023-08-25	Annually	0.00%
ORBN	Ex Dividend Junior	2023-09-29	Quarterly	0.00%
CLLNY	Ex Dividend Junior	2023-06-16	Semi-Annually	0.00%
WEGZY	Ex Dividend King	2023-09-29	Bi-Monthly	0.00%
HSQVY	Ex Dividend Junior	2023-10-05	Annually	0.00%
RCBC	Ex Dividend Junior	2023-07-31	Quarterly	0.00%
CSXXY	Ex Dividend Knight	2023-09-15	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0243	1.500	-0.486	-0.729	[0 - 0.5]
returnOnAssetsTTM	-0.0149	1.200	-0.498	-0.598	[0 - 0.3]
returnOnEquityTTM	-0.0337	1.500	-1.486	-2.23	[0.1 - 1]
payoutRatioTTM	-1.778	-1.000	-10.00	10.00	[0 - 1]
currentRatioTTM	1.354	0.800	8.23	6.59	[1 - 3]
quickRatioTTM	0.603	0.800	-1.161	-0.929	[0.8 - 2.5]
cashRatioTTM	0.122	1.500	-0.435	-0.653	[0.2 - 2]
debtRatioTTM	0.287	-1.500	5.21	-7.82	[0 - 0.6]
interestCoverageTTM	3.11	1.000	9.96	9.96	[3 - 30]
operatingCashFlowPerShareTTM	7.60	2.00	7.47	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.58	2.00	7.21	10.00	[0 - 20]
debtEquityRatioTTM	0.654	-1.500	7.38	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.231	1.000	9.48	9.48	[0.2 - 0.8]
operatingProfitMarginTTM	0.0599	1.000	-0.803	-0.803	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.337	1.000	9.24	9.24	[0.2 - 2]
assetTurnoverTTM	0.616	0.800	9.23	7.38	[0.5 - 2]
Total Score				6.26

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-6.24	1.000	-0.731	0	[1 - 100]
returnOnEquityTTM	-0.0337	2.50	-0.955	-2.23	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.58	2.00	8.14	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	7.60	2.00	7.47	10.00	[0 - 30]
payoutRatioTTM	-1.778	1.500	-10.00	10.00	[0 - 1]
pegRatioTTM	-1.590	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.157	1.000	8.57	0	[0.1 - 0.5]
Total Score				0.545

Fresenius SE & Co. KGaA Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Realtime updates for Fresenius SE & Co. KGaA [FSNUY]

Upcoming Earnings Alert